Increased Patients from Fine Dust in Spring... Be Careful When Using Medical Inhalers
As respiratory disease patients rise due to fine dust and significant temperature changes in spring, the South Korean Ministry of Food and Drug Safety has issued advice on the safe use of medical inhalers.
During the spring season when significant day-night temperature differences and fine dust levels rise, there has been an increase in patients suffering from respiratory diseases. This situation necessitates careful attention to the use of home medical inhalers, known as nebulizers. The Korean Ministry of Food and Drug Safety (MFDS) has provided safety guidance for using these devices safely to ensure proper treatment and minimize risks associated with infections and device misuse.
Medical inhalers are classified as class II medical devices used to administer liquid medications in gas form directly to the lungs, and they can be categorized based on their vaporizing method: heated, unheated, or ultrasonic. The MFDS emphasizes the importance of consulting with a healthcare professional before using an inhaler, and strictly adhering to the prescribed medication type and dosage. Users are advised to read the instruction manuals carefully, as some devices are reusable after cleaning and sterilization, while others are intended for single use.
Particularly crucial is the prevention of bacterial growth in nebulizer components, such as spray cups and masks. It is essential to clean, disinfect, and thoroughly dry these parts to avoid contamination. Regular checks should be conducted for any signs of wear or leaks, and it is vital to replace consumables following the manufacturer's instructions. High-risk groups, including children, the elderly, and individuals with chronic respiratory conditions, require vigilant supervision as contaminated devices can increase the risk of infections. Lastly, when using these inhalers, any signs of worsened cough, breathlessness, or dizziness warrant immediate cessation of use, and consumers are encouraged to report adverse effects through the MFDS’s designated reporting platform.